Klinik für Neonatologie, Frauenklinikstrasse 10, 8091 Zürich, CH.
Swiss Med Wkly. 2011 Feb 16;141:w13145. doi: 10.4414/smw.2011.13145. eCollection 2011.
Perinatal asphyxial encephalopathy occurs in 1 per 1000 live births and is associated with high mortality and morbidity. Therapeutic hypothermia increases intact survival and improves neurodevelopmental outcome in survivors.
To evaluate (i) the opinion and practice of therapeutic hypothermia as a therapy for moderate to severe perinatal asphyxial encephalopathy amongst Swiss neonatologists and paediatric intensive care specialists, (ii) the current clinical management of infants with perinatal asphyxial encephalopathy and (iii) the need for a national perinatal asphyxia and therapeutic hypothermia registry.
Two web-based questionnaires were sent to 18 senior staff physicians within the Swiss Neonatal Network.
Therapeutic hypothermia was considered effective by all responders, however only 11 of 18 units provided therapeutic hypothermia. Cooling was initiated during transfer and performed passively in 82% of centres with a target rectal temperature of 33-34 °C. Most units ventilated infants with perinatal asphyxial encephalopathy if clinically indicated and 73% of responders gave analgesia routinely to cooled infants. Neuromonitoring included continuous amplitude integrated EEG (aEEG) and EEG. Neuroimaging included cranial ultrasound (cUS), magnetic resonance imaging (MRI) and computed tomography (CT). Sixty-seven percent of units treating infants with perinatal asphyxial encephalopathy performed MRI routinely. All heads of departments questioned indicated that a "Swiss National Asphyxia and Cooling Registry" is needed.
In Switzerland, access to therapeutic hypothermia is widespread and Swiss neonatologists believe that therapeutic hypothermia for perinatal asphyxia is effective. National cooling protocols are needed for the management of infants with perinatal asphyxial encephalopathy in order to ensure safe cooling, appropriate monitoring, imaging and follow-up assessment. A national registry is needed to collect data on diagnosis, treatment, adverse events and outcome.
围产期窒息性脑病在活产儿中发生率为 1/1000,与高死亡率和发病率相关。治疗性低温可提高完整存活率并改善幸存者的神经发育结局。
评估(i)瑞士新生儿科医生和儿科重症监护专家对治疗性低温作为中重度围产期窒息性脑病治疗方法的看法和实践,(ii)患有围产期窒息性脑病的婴儿的当前临床管理,以及(iii)建立全国围产期窒息和治疗性低温登记处的必要性。
向瑞士新生儿网络的 18 名高级主治医生发送了两份基于网络的问卷。
所有应答者均认为治疗性低温有效,但只有 18 个单位中的 11 个提供了治疗性低温。冷却在转移期间开始,并在 82%的中心通过被动方式进行,直肠温度目标为 33-34°C。大多数单位在临床需要时对患有围产期窒息性脑病的婴儿进行通气,73%的应答者常规对冷却的婴儿给予镇痛。神经监测包括连续振幅整合脑电图(aEEG)和脑电图。神经影像学包括头颅超声(cUS)、磁共振成像(MRI)和计算机断层扫描(CT)。67%的治疗围产期窒息性脑病婴儿的单位常规进行 MRI。所有被问到的科室主任都表示需要建立一个“瑞士国家窒息和冷却登记处”。
在瑞士,治疗性低温的应用广泛,瑞士新生儿科医生认为治疗性低温对围产期窒息有效。为了确保安全冷却、适当监测、影像学和随访评估,需要制定全国性的冷却方案来管理围产期窒息性脑病婴儿。需要建立一个国家登记处来收集关于诊断、治疗、不良事件和结局的数据。